Pro Share Advisors LLC Trevi Therapeutics, Inc. Transaction History
Pro Share Advisors LLC
- $48.7 Billion
- Q2 2025
A detailed history of Pro Share Advisors LLC transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 19,355 shares of TRVI stock, worth $198,388. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,355
Previous 20,160
3.99%
Holding current value
$198,388
Previous $126,000
16.67%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding TRVI
# of Institutions
165Shares Held
110MCall Options Held
1.08MPut Options Held
425K-
Nea Management Company, LLC Timonium, MD13.2MShares$136 Million6.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.3MShares$105 Million2.96% of portfolio
-
Rubric Capital Management LP New York, NY8.53MShares$87.5 Million1.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.32MShares$54.5 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA4.49MShares$46 Million5.2% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $598M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...